Cartilage Affecting Patents (Class 514/17.1)
-
Patent number: 11896642Abstract: Provided herein are synthetic bioconjugates comprising collagen-binding peptides covalently bound to chemically modified glycan backbones, compositions containing the same, and uses thereof.Type: GrantFiled: July 9, 2018Date of Patent: February 13, 2024Assignee: Symic Holdings, Inc.Inventors: John Eric Paderi, Glenn Prestwich, Katherine Allison Stuart, Harsha Kabra, Elvis Ikwa
-
Patent number: 11351223Abstract: The invention provides methods and compositions for the treatment of cartilage damage or arthritis by administration of a protease-resistant ANGPTL3 polypeptide with chondrogenic activity.Type: GrantFiled: November 13, 2017Date of Patent: June 7, 2022Assignee: Novartis AGInventors: Jörg Goldhahn, Kristen Johnson, Celeste Scotti, Igor Vostiar
-
Patent number: 11041006Abstract: The present invention provides compositions for use in recovering and/or ameliorating deterioration of physiological functions due to aging. Provided are: a cell overexpressing GDF6 protein or an miR-17 family member; a composition for use in treating a senescence-related condition, containing GDF6 protein; a composition for use in treating a senescence-related condition, containing a human expression vector for GDF6 protein or an miR-17 family member; and a composition for use in treating a senescence-related condition, containing a cell secreting GDF6 protein.Type: GrantFiled: December 27, 2016Date of Patent: June 22, 2021Assignee: RIKENInventor: Hayato Kaneda
-
Patent number: 10532069Abstract: Compositions and methods are disclosed for the treatment of osteoarthritis. The compositions comprising combinations of hyaluronic acid, glucosamine, and chondroitin sulfate, can be useful for any synovial joint, including the knee, shoulder, hip, ankle, hands, spinal facet, or temporomandibular joint, both for the relief of pain and for slowing disease progression.Type: GrantFiled: June 2, 2017Date of Patent: January 14, 2020Assignee: DEPUY SYNTHES PRODUCTS, INC.Inventors: Brooks J. Story, Scott A. Wadsworth, William R. Parrish, Uri Herzberg, Donna Torres, Benjamin A. Byers, Julia Hwang, Dongling Su
-
Patent number: 10047123Abstract: The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. The present invention relates to 30 peptide sequences and their variants derived from HLA class I and class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses.Type: GrantFiled: August 2, 2016Date of Patent: August 14, 2018Assignee: IMMATICS BIOTECHNOLOGIES GMBHInventors: Toni Weinschenk, Oliver Schoor, Claudia Trautwein, Norbert Hilf, Steffen Walter, Harpreet Singh
-
Publication number: 20150141344Abstract: The present invention relates to a composition for repairing cartilage tissue, to a method for producing same, and to the use thereof. The present invention provides a composition for repairing cartilage tissue, which is obtained by mixing collagen and hyaluronic acid using a two-way syringe or a mixer, wherein the collagen has a diluted concentration of 5-60 mg/mL excepting water or a physiological phosphate buffer solution, and the hyaluronic acid has a diluted concentration of 5-20 mg/mL excepting water or a physiological phosphate buffer solution.Type: ApplicationFiled: June 8, 2012Publication date: May 21, 2015Applicant: SEWON CELLONTECH CO., LTD.Inventors: Se Ken Yeo, Cheong Ho Chang, Ji Chul Yoo, Dong Sam Suh, Jun Keun Lee, Sang Hun Woo
-
Publication number: 20150133367Abstract: The present invention includes a novel class of highly specific protease inhibitors. In one embodiment, the inhibitors of the invention are ?-helical in structure. In another embodiment, the present invention represents the first demonstration of a highly specific cysteine protease inhibitor.Type: ApplicationFiled: April 26, 2013Publication date: May 14, 2015Inventor: Doron C. Greenbaum
-
Publication number: 20150126452Abstract: The present invention relates to a method for assembling (monomeric or oligomeric) proteins and peptide structures to multimeric protein or peptide structures. The present invention also provides a method for preparing peptide based polymers by crosslinking such multimeric proteins or peptides obtainable according to the inventive method and their use as polymers, for amphiphilic applications, as protein based detergents, for forming artificial organelles, etc. Disclosed are furthermore novel protein or peptide structures, nucleic acids encoding same and cloning and expression vectors suitable for carrying out the inventive method for assembling multimeric proteins or peptides.Type: ApplicationFiled: May 28, 2013Publication date: May 7, 2015Inventors: Stefan Schiller, Matthias Huber
-
Patent number: 8987205Abstract: Recombinant lubricin molecules and uses thereof. Novel recombinant lubricin molecules and their uses as lubricants, anti-adhesive agents and/or intra-articular supplements for, e.g., synovial joints, meniscus, tendon, peritoneum, pericardium and pleura, are provided.Type: GrantFiled: March 8, 2013Date of Patent: March 24, 2015Assignee: Wyeth LLCInventors: Carl Ralph Flannery, Christopher John Corcoran, Bethany Annis Freeman, Lisa A. Collins-Racie
-
Patent number: 8987201Abstract: Black bear parathyroid hormone (PTH) and functional fragments thereof are provided. Also provided are methods of using black bear PTH and functional fragments for increasing cAMP in a bone-forming cell; reducing apoptosis in a bone-forming cell; decreasing the ratio of expression levels of Bax protein to Bcl-2 protein in a bone-forming cell; increasing the expression level of one or more of a bone matrix protein, a transcriptional activator, or a transcriptional regulator in a bone-forming cell; enhancing bone mineral density, increasing bone mass, decreasing bone loss, or reducing the incidence of bone fractures, or any combination thereof, in a subject; also provided are antibodies directed against black bear parathyroid hormone (PTH) and functional fragments thereof.Type: GrantFiled: December 7, 2009Date of Patent: March 24, 2015Assignee: Michigan Technological UniversityInventor: Seth W. Donahue
-
Publication number: 20150065428Abstract: The invention is a method of applying a joint inducing protein preferably BMP-9 or BMP-3 to an ossification center in order to create a joint, articular cartilage, or an endochondral cap. The ossification center may be one that occurs naturally such as in the case of amputation, wound healing or fracture, or, it may be artificially induced by the application of an ossification center inducing protein, which may include other BMP family proteins such as BMP-2, BMP-4 or BMP-7. Further, this invention is a method of producing joints, or joint-like structures in vitro by application of BMP-9 to cells derived from tissue regions capable of producing ossification centers, such as digit-derived fibroblasts.Type: ApplicationFiled: August 31, 2013Publication date: March 5, 2015Inventors: Ken Muneoka, Minqan Yan, Ling Yu
-
Patent number: 8969301Abstract: Provided are compositions comprising newly identified protein fragments of aminoacyl-tRNA synthetases, polynucleotides that encode them and complements thereof, related agents, and methods of use thereof in diagnostic, drug discovery, research, and therapeutic applications.Type: GrantFiled: July 11, 2011Date of Patent: March 3, 2015Assignees: aTyr Pharma Inc., Pangu BioPharma LimitedInventors: Leslie Ann Greene, Kyle P. Chiang, Fei Hong, Alain Philippe Vasserot, Wing-Sze Lo, Jeffry D. Watkins, Cheryl L. Quinn, John D. Mendlein
-
Publication number: 20150057229Abstract: A method for inhibiting cartilage degradation comprising administering to a subject a therapeutically effective amount of a polypeptide comprising or consisting of a Link_TSG6 polypeptide is disclosedType: ApplicationFiled: September 9, 2014Publication date: February 26, 2015Inventors: Anthony Day, Caroline Milner, Sheona Patricia Drummond
-
Patent number: 8940698Abstract: Cartilage materials such as cartilage fluff and a cartilage composition comprising a particulate material are disclosed. These are suitable for stimulating chondrogenesis and/or producing cartilage regeneration. Also disclosed are processes for their preparation. Methods for regenerating articular cartilage are also disclosed, which involve, for example, placing the cartilage fluff or cartilage composition into a cartilage defect.Type: GrantFiled: August 14, 2013Date of Patent: January 27, 2015Assignee: Vivex Biomedical, Inc.Inventor: Theodore I. Malinin
-
Patent number: 8927491Abstract: Methods and compositions are disclosed for an intra-articular injection for the treatment of osteoarthritis. The methods and compositions comprising combinations of hyaluronic acid and a bone morphogenetic protein, like rhGDF-5, can be useful for any synovial joint, including the knee, shoulder, hip, ankle, hands, spinal facet, or temporomandibular joint, both for the relief of pain and for slowing disease progression.Type: GrantFiled: March 7, 2013Date of Patent: January 6, 2015Assignee: DePuy Mitek, LLCInventors: Benjamin A. Byers, Dongling Su, Julia Hwang
-
Patent number: 8927493Abstract: An object of the present invention is to provide a drug for promoting the regeneration of tendon-bone junction tissue or ligament-bone junction tissue.Type: GrantFiled: October 8, 2009Date of Patent: January 6, 2015Assignee: Kringle Pharma, Inc.Inventors: Katsuro Tomita, Hiroyuki Tsuchiya, Katsuhiko Kitaoka, Junsuke Nakase, Keigo Hanada, Kunio Matsumoto
-
Patent number: 8916517Abstract: This invention relates to novel analogs of pituitary adenylate cyclase-activating polypeptide (PACAP), which are agonists for the PACAP/vasoactive intestinal peptide (VIP) receptors: PAC1, VPAC1 and VPAC2 receptors. These PACAP analogs can be used as prophylactic/therapeutic agents for a wide range of medical disorders, including (but not limited to) cancer and autoimmune disease. These PACAP analogs can be coupled to suitable radionuclides and used in the localization, diagnosis and treatment of disseminated cancers and metastatic tumors, or coupled to small molecule therapeutics and used as vectors for targeted drug delivery. This invention also provides pharmaceutical compositions of one or more PACAP-like compounds of the invention either alone or in combination with one or more other prophylactic/therapeutic agents.Type: GrantFiled: November 2, 2010Date of Patent: December 23, 2014Assignee: The Administrators of the Tulane Educational FundInventors: David H. Coy, Jerome L. Maderdrut, Min Li
-
Publication number: 20140364372Abstract: A method of treating an injury to hyaline cartilage in a subject in need thereof. The method comprises administering to the subject a therapeutically effective amount of amelogenin.Type: ApplicationFiled: August 28, 2014Publication date: December 11, 2014Inventors: Dan DEUTSCH, Amir Haze, Anat Blumenfeld
-
Patent number: 8900579Abstract: Novel antibodies and antigen binding fragments that specifically binds to Siglec-15 are described herein In some embodiments, the antibodies or antigen binding fragments may block the biological activity of Siglec-15 and are useful in composition for the treatment of bone loss, more particularly in bone diseases that have increased cell surface expression of Siglec-15, such as conditions where there is an increase in the bone degradative activity of osteoclasts The invention also relates to cells expressing the antibodies or antigen binding fragments such as monoclonal, humanized or chimeric antibodies Additionally, methods of detecting and treating bone loss, bone-related diseases or cancer using the antibodies and fragments are also disclosed.Type: GrantFiled: January 7, 2014Date of Patent: December 2, 2014Assignee: Alethia Biotherapuetics Inc.Inventors: Gilles Bernard Tremblay, Mario Filion, Matthew Stuible
-
Patent number: 8895506Abstract: The present invention is directed to stabilizing Bone Morphogenetic Protein in various lyophilized formulations and compositions. The present invention comprises formulations primarily including trehalose as an excipient for lyophilized compositions and their subsequent storage and reconstitution, and can also optionally include other excipients, including buffers and surfactants.Type: GrantFiled: March 7, 2013Date of Patent: November 25, 2014Assignee: DePuy Synthes Products, LLCInventors: Venkata R. Garigapati, Dongling Su, Rehan Khanzada, Steven J. Sawamura
-
Publication number: 20140342983Abstract: The present invention provides compounds for disrupting the binding of a matrix metalloprotease (MMP) protein to a substrate protein at an interaction site other than the protease catalytic site. In particular the inventive compounds inhibit the MMP's ability to cleave a substrate protein. In some cases the compound may prevent activation of transforming growth factor beta (TGF?). The compounds are preferably polypeptide fragments of the hemopexin-like domain of the MMP, but may be mimetics thereof or peptides or mimetics of the portion of the MMP substrate protein to which the MMP interacts.Type: ApplicationFiled: April 28, 2014Publication date: November 20, 2014Inventors: Marina D'Angelo, Abdulhafez Selim
-
Patent number: 8877712Abstract: Methods and compositions are described enhancing bone density or formation, including for stabilizing bone grafts, bone repair, joint replacement, and cartilage repair that includes providing a composition including Del-1 locally to a site for enhancing bone density or formation, or to a culture or chondrocytes or multipotent chondrocyte precursor cells, whereby survival or differentiation of chondrocytes at the site is enhanced, thereby ultimately enhancing bone density or formation. Methods and compositions for stimulating hair regrowth are also provided.Type: GrantFiled: April 6, 2007Date of Patent: November 4, 2014Assignee: The Board of Trustees of the Leland Stanford Junior UniversityInventors: George P Yang, Jonathan A. Mathy, Thomas Quertermous
-
Patent number: 8871710Abstract: This invention relates to the production and use of pharmaceutical growth factor compositions with novel characteristics, e.g. improved solubility and controlled release characteristics under physiological conditions. The compositions of one or more precursor proteins of growth factors of the GDF family provoke morphogenic effects such as growth, differentiation, protection and regeneration of a variety of tissues and organs, e.g. bone, cartilage, tendons, ligaments, nerves and skin. The compositions can be advantageously used for the healing of tissue-destructive injuries and for the prevention or therapy of degenerative disorders.Type: GrantFiled: December 20, 2012Date of Patent: October 28, 2014Assignee: Biopharm Gesellschaft zur biotechnologischen Entwicklung von Pharmaka mbHInventors: Jens Pohl, Frank Ploeger
-
Publication number: 20140301983Abstract: This invention pertains to the field of hyaluronic acid-binding synthetic peptidoglycans and methods of forming and using the same.Type: ApplicationFiled: May 24, 2012Publication date: October 9, 2014Applicant: PURDUE RESEARCH FOUNDATIONInventors: Alyssa Panitch, Jonathan C. Bernhard, John E. Paderi, Shaili Sharma
-
Publication number: 20140303087Abstract: Thrombospondin 1 (TSP-1), TSP-2, interleukin 17B receptor (IL-17BR) and heparin-binding epidermal growth factor-like growth factor (HB-EGF) associated with stem cell activity and use thereof.Type: ApplicationFiled: June 19, 2013Publication date: October 9, 2014Applicant: MEDIPOST CO., LTD.Inventors: Yoon-Sun YANG, Won IL Oh, Hong Bae Jeon, Mee Hyun Jung, Sang Young Jeong
-
Patent number: 8853361Abstract: The invention relates to a sterile preparation which can be implanted on or in organic tissues, comprising: a natural or modified globin material which is insoluble at physiological pH and/or a material obtainable from globin which has been modified to be soluble at physiological pH, the said materials being biocompatible and biodegradable in the organism; an agent selected from natural or synthetic polymeric adhesive agents, polymeric tissue enhancement or filling agents, more particularly an agent based on crosslinked hyaluronic acid or on polylactic acid, and a polymeric wound cicatrization agent, specifically oxidized cellulose; with the provisos that, if the preparation comprises the said material obtainable from globin modified so as to be at least partly soluble, the said polymeric adhesive agent, if present, is not hyaluronic acid or carboxymethylcellulose and the said polymeric enhancement or filling agent, if present, is an agent based on crosslinked hyaluronic acid, and that, if the preparation comType: GrantFiled: January 24, 2007Date of Patent: October 7, 2014Assignee: KhorionyxInventor: Jean-Louis Tayot
-
Publication number: 20140288002Abstract: This disclosure provides extracellular matrix-binding synthetic peptidoglycans comprised of one or more synthetic peptides conjugated to a glycan and methods of their use.Type: ApplicationFiled: March 14, 2014Publication date: September 25, 2014Inventors: Alyssa Panitch, John Eric Paderi, Shaili Sharma, Katherine Allison Stuart, Nelda Marie Vazquez-Portalatin
-
Publication number: 20140289882Abstract: The present inventions are directed to compositions and methods regarding the reprogramming of other cells (such as embryonic stem cells (ESCs), induced pluripotent stem cells (iPSCs), MSCs, fibroblasts, hematopoietic stem cells, endothelian stem cells, adipocytes, chondrocytes, osteoblasts, osteoclasts and endothelial cells) into chondrogenic cells without introducing exogenous genes to the samples. In particular, the present inventions are directed to transducible materials that are capable of transducing into the biological samples but are not genes or causing genetic modifications. The present inventions also are directed to methods of reprogramming the path of biological samples or treating diseases using the tranducible compositions thereof.Type: ApplicationFiled: July 19, 2012Publication date: September 25, 2014Applicants: OREGON HEALTH AND SCIENCE UNIVERSITY, VIVOSCRIPT, INC.Inventors: Yong Zhu, Shili Wu, Jun Bao, Cong-Qiu Chu
-
Publication number: 20140256643Abstract: The present invention provides new protease resistant polypeptides, as well as compositions and methods for treating, ameliorating or preventing conditions related to joint damage, including acute joint injury and arthritis.Type: ApplicationFiled: March 7, 2014Publication date: September 11, 2014Inventors: Kristen JOHNSON, Jian SHI
-
Publication number: 20140256641Abstract: Isolated polypeptides are disclosed comprising an amino acid sequence encoding a monomer of a fibrous polypeptide attached to a heterologous polysaccharide binding domain. Composites comprising same, methods of generating same and uses thereof are all disclosed.Type: ApplicationFiled: March 13, 2014Publication date: September 11, 2014Applicants: CollPlant Ltd., Yissum Research Development Company of the Hebrew University of Jerusalem Ltd.Inventors: Oded SHOSEYOV, Shaul Lapidot, Sigal Meirovitch, Daniel L. Siegel
-
Patent number: 8828937Abstract: The present invention is directed to an isolated peptide comprising or consisting of an amino acid sequence with an amino acid identity of at least 90% compared to mature human BMP2 with SEQ ID No. 1, characterized in that said amino acid sequence comprises at least two amino acid substitutions characterized in that a first amino acid substitution occurs at a position corresponding to N59, S88, E94, V99, K101 and/or N102 of SEQ ID No. 1 and to uses thereof.Type: GrantFiled: March 11, 2010Date of Patent: September 9, 2014Assignee: Haase Investments UGInventors: Petra Seemann, Stefan Mundlos, Carsten Reissner, Georg Duda, Julia Zimmer
-
Patent number: 8828941Abstract: The present invention provides compositions of matter suitable for the prevention of and/or treatment of a spinal disorder and/or spinal pain, e.g., caused by and/or associated with intervertebral disc (IVD) degeneration, and methods of treatment of a spinal disorder and/or spinal pain. For example, the compositions of the present invention comprise a modulator of growth differentiation factor (GDF)-6 signaling sufficient to reduce or prevent or delay IVD degeneration and/or to enhance or induce IVD regeneration. The present invention also provides medical devices comprising such compositions, and methods of treatment making use of such compositions.Type: GrantFiled: February 22, 2008Date of Patent: September 9, 2014Inventors: Ashish Diwan, Divya Diwan
-
Publication number: 20140242140Abstract: Fabrication method for stratified and layered tissue to repair osteochondral defects. In a method of the present disclosure, the method comprises the step of applying a first direction magnetic field to a first quantity of a first collagen solution to align collagen within the first collagen solution in a first direction relative to the first direction magnetic field, forming a first layer of collagen. In a method of generating an aligned collagen layer of the present disclosure, the method comprises applying a first magnetic field at or greater than 0.1 Tesla to a layer of a first collagen solution defining a horizontal plane, within a temperature at or between 2° C. and 45° C., to generate an aligned collagen layer.Type: ApplicationFiled: February 28, 2014Publication date: August 28, 2014Applicant: Purdue Research FoundationInventors: Corey P. Neu, Tyler A. Novak, Garrett Shannon
-
Patent number: 8815803Abstract: This invention provides a composition for increasing a body height of a patient with short stature or an individual other than patients with short stature. More specifically, the invention provides: a composition for increasing the body height of an individual comprising a guanyl cyclase B (GC-B) activator as an active ingredient, the composition being to be administered to an individual free from FGFR3 abnormality; a method for increasing the body height of an individual free from FGFR3 abnormality which comprises activating GC-B; a method for screening an agent for increasing the body height of an individual which comprises selecting an agent for increasing the body height using GC-B activity as an indication; and a method for extending a cartilage bone free from FGFR3 abnormality which comprises activating GC-B in an individual.Type: GrantFiled: March 31, 2005Date of Patent: August 26, 2014Inventors: Kazuwa Nakao, Akihiro Yasoda, Hidetomo Kitamura
-
Patent number: 8802626Abstract: Disclosed herein are improved osteogenic devices and methods of use thereof for repair of bone and cartilage defects. The devices and methods promote accelerated formation of repair tissue with enhanced stability using less osteogenic protein than devices in the art. Defects susceptible to repair with the instant invention include, but are not limited to: critical size defects, non-critical size defects, non-union fractures, fractures, osteochondral defects, subchondral defects, and detects resulting from degenerative diseases such as osteochondritis dessicans.Type: GrantFiled: March 18, 2011Date of Patent: August 12, 2014Assignee: Stryker CorporationInventors: David C. Rueger, Marjorie M. Tucker, An-Cheng Chang
-
Publication number: 20140221294Abstract: This invention relates to oral and intra-articular formulations based on sulphated hyaluronic acid which are effective in the treatment of degenerative osteoarthritis.Type: ApplicationFiled: April 11, 2014Publication date: August 7, 2014Inventors: Lanfranco CALLEGARO, Davide RENIER
-
Publication number: 20140213524Abstract: A novel composition for regenerating a cartilage has been demanded, which can achieve a good effect of regenerating a hyaline cartilage that is a nearly normal cartilage without requiring the use of any transplanted cell. The present invention provides a composition for regenerating a cartilage, wherein (a) a monovalent metal salt of low endotoxin alginic acid and (b) SDF-1 are used in combination.Type: ApplicationFiled: August 22, 2012Publication date: July 31, 2014Inventors: Norimasa Iwasaki, Atsushi Sukegawa, Akio Minami, Nobuo Ohzawa
-
Patent number: 8791071Abstract: Cartilage materials such as cartilage fluff and a cartilage composition comprising a particulate material are disclosed. These are suitable for stimulating chondrogenesis and/or producing cartilage regeneration. Also disclosed are processes for their preparation. Methods for regenerating articular cartilage are also disclosed, which involve, for example, placing the cartilage fluff or cartilage composition into a cartilage defect.Type: GrantFiled: April 7, 2014Date of Patent: July 29, 2014Assignee: Vivex Biomedical, Inc.Inventor: Theodore I. Malinin
-
Publication number: 20140193468Abstract: The invention generally relates to systems (i.e. constructs) for repairing cartilage and methods for preparing the same that introduce a bioactive agent into a culture medium, suspension, scaffold, solution incorporated into the pores of the scaffold, or combinations thereof. The introduction of a bioactive agent promotes production of neo-cartilage (i.e. immature hyaline cartilage) in the system, both ex-vivo and in-vivo.Type: ApplicationFiled: March 13, 2014Publication date: July 10, 2014Applicant: HISTOGENICS CORPORATIONInventors: Laurence J. B. Tarrant, Sonya Shortkroff, Shuichi Mizuno, Akihiko Kusanagi, Toshimasa Tokuno, Robert Lane Smith
-
Patent number: 8772241Abstract: The present invention provides a peptide represented by formula (I) of X1-Leu-X2-Leu-X3 wherein X1 represents Glu or Asp, X2 represents His, Lys or Arg, X3 represents Asp or Glu, with Glu, Asp, Leu, His, Lys and Arg being respectively glutamic acid, aspartic acid, leucine, histidine, lysine and arginine; or a pharmaceutically acceptable salt thereof; a composition for the treatment or prevention of at least one selected from cartilage damage and arthritis, containing the same peptide or a pharmaceutically acceptable salt thereof as an active ingredient; and a composition containing the same peptide or a pharmaceutically acceptable salt thereof and TGF?1.Type: GrantFiled: June 22, 2011Date of Patent: July 8, 2014Assignee: Ensoltek Co., Ltd.Inventors: Hae Jin Kim, Je Wook Lee, Young Joon Kwon, Eun Joung Moon
-
Patent number: 8765675Abstract: The present invention relates to a novel use of calcitonin in osteoarthritis, and to methods of treating and/or preventing osteoarthritis in mammals, particularly humans.Type: GrantFiled: June 21, 2010Date of Patent: July 1, 2014Assignee: Novartis AGInventors: Moise Azria, Claus Christiansen, Simon David Bateman, Shoufeng Li
-
Patent number: 8759296Abstract: A cyclized peptide designated BMP Binding Peptide (BBP) is a synthetic peptide that avidly binds rhBMP-2. BBP increases the overall osteogenic activity of rhBMP-2, increases the rate at which rhBMP-2 induces bone formation, and BBP induces calcification alone. Compositions and substrates including BBP, and methods of using BBP are useful in therapeutic, diagnostic and clinical applications requiring calcification and osteogenesis.Type: GrantFiled: May 25, 2012Date of Patent: June 24, 2014Assignees: The Regents of The University of California, The United States of America as Represented by The Department of Veterans AffairsInventors: Samuel S. Murray, Keyvan Behnam, Elsa J. Brochmann-Murray
-
Publication number: 20140170106Abstract: The methods and compositions disclosed herein are effective in the promoting the reattachment of delaminated cartilage to bone. The methods (and related compositions) comprise the removal of the acellular layer of the delaminated cartilage thereby exposing the underlying chondrocyte cells thereby allowing the promotion of the reattachment of the delaminated cartilage.Type: ApplicationFiled: November 8, 2013Publication date: June 19, 2014Inventors: Kelsey Jean Carvell, Ruth Cheng, Graham Smith, Drew Burdon
-
Patent number: 8709997Abstract: Subjects lacking Nfat1 display osteoarthritis in weight-bearing joints. Osteoarthritic changes associated with Nfat1 deficiency are characterized by articular cartilage degradation, articular chondrocyte proliferation/clustering, progressive articular surface destruction, periarticular chondro-osteophyte formation, and exposure of thickened subchondral bone. Methods of treating osteoarthritis, methods of diagnosis and early prediction of the onset of osteoarthritis, and methods for screening drug candidates that may be useful for treatment of osteoarthritis are presented.Type: GrantFiled: August 31, 2012Date of Patent: April 29, 2014Assignee: University of KansasInventor: Jinxi Wang
-
Patent number: 8710014Abstract: The present invention provides compounds for disrupting the binding of a matrix metalloprotease (MMP) protein to a substrate protein at an interaction site other than the protease catalytic site. In particular the inventive compounds inhibit the MMP's ability to cleave a substrate protein. In some cases the compound may prevent activation of transforming growth factor beta (TGF?). The compounds are preferably polypeptide fragments of the hemopexin-like domain of the MMP, but may be mimetics thereof or peptides or mimetics of the portion of the MMP substrate protein to which the MMP interacts.Type: GrantFiled: October 7, 2011Date of Patent: April 29, 2014Assignee: ProteaPex Therapeutics LLCInventors: Marina D'Angelo, Abdulhafez Selim
-
Patent number: 8697139Abstract: Harvesting articular chondrocyte cells from a non-critical location of a patient and growing additional cells for transplantation into a damaged or diseased disc of the patient.Type: GrantFiled: September 21, 2004Date of Patent: April 15, 2014Inventor: Frank Martin Phillips
-
Publication number: 20140066376Abstract: Provided herein are compositions and methods related to promoting protection or repair of articular cartilage and/or musculoskeletal soft tissue by contacting the cartilage, tissues or cellular components thereof with a parathyroid hormone/parathyroid hormone-related protein (PTH/PTHrP) receptor agonist or releasing factor.Type: ApplicationFiled: August 20, 2013Publication date: March 6, 2014Applicant: UNIVERSITY OF ROCHESTERInventors: Randy N. Rosier, Michael J. Zuscik, Erik Sampson, Susan V. Bukata, J. Edward Puzas, Hani Awad
-
Patent number: 8652530Abstract: The instant invention is the storage of Type II collagen containing tissue in carbonated water. Such Type II collagen is useful for alleviating the symptoms of arthritis in mammals as well as the treatment of arthritis in mammals. Such Type II collagen is also useful for the prevention of arthritis in mammals. The instant invention is also a method for the preparation of a nutritional supplement that includes the steps of: (a) separating water-insoluble undenatured Type II collagen containing animal tissue from animal tissue not containing Type II collagen; (b) subdividing and sterilizing said tissue under conditions which do not change the original structure of the Type II collagen to produce a subdivided and sterilized product; (c) packaging the subdivided and sterilized product in carbonated water.Type: GrantFiled: May 15, 2013Date of Patent: February 18, 2014Assignee: Cartilast Corp.Inventor: Eugene R. Moore
-
Publication number: 20130337074Abstract: The present invention relates to a composition comprising, or consisting of 2-50 mg/ml hyaluronic acid, 0.1-500 mg/ml of biodegradable particles with an average mean particle diameter of 1 nm-500 ?m, 1 pg/ml-10 ?g/ml cytokines, where the concentrations specified are based in each case on the total volume (w/v) of the composition and where the cytokines are enclosed in the biodegradable particles, and to their use in the treatment of cartilage defects, for example traumatic cartilage defects or osteoarthrosis.Type: ApplicationFiled: November 30, 2011Publication date: December 19, 2013Inventors: Kristin Andreas, Jochen Ringe, Michael Sittinger
-
Publication number: 20130324473Abstract: The invention relates to the preparation and provision of a gelling collagen composition that instantaneously forms a collagen matrix, and means for the preparation and use thereof, in particular as part of a therapeutic treatment.Type: ApplicationFiled: January 26, 2012Publication date: December 5, 2013Applicant: AMEDRIX GmbHInventor: Thomas Graeve